We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Two ANDA Decisions Could Signal More Conservative FDA
Two ANDA Decisions Could Signal More Conservative FDA
March 13, 2012
Recent FDA action on two ANDAs could signal a new, more conservative trend in not granting 180-day exclusivities for first-filing generic-drug makers in less obvious situations, an industry attorney says.